View Item 

Show simple item record

The hepatotoxicity of non-steroidal anti-inflammatory drugs

dc.contributor.authorRubenstein, Joel H.en_US
dc.contributor.authorLaine, Lorenen_US
dc.date.accessioned2010-06-01T19:44:05Z
dc.date.available2010-06-01T19:44:05Z
dc.date.issued2004-08en_US
dc.identifier.citationRubenstein, J. H.; Laine, L. (2004). "The hepatotoxicity of non-steroidal anti-inflammatory drugs." Alimentary Pharmacology & Therapeutics 20(4): 373-380. <http://hdl.handle.net/2027.42/72868>en_US
dc.identifier.issn0269-2813en_US
dc.identifier.issn1365-2036en_US
dc.identifier.urihttps://hdl.handle.net/2027.42/72868
dc.identifier.urihttp://www.ncbi.nlm.nih.gov/sites/entrez?cmd=retrieve&db=pubmed&list_uids=15298630&dopt=citationen_US
dc.format.extent75769 bytes
dc.format.extent3109 bytes
dc.format.mimetypeapplication/pdf
dc.format.mimetypetext/plain
dc.publisherBlackwell Science Ltden_US
dc.rights2004 Blackwell Publishing Ltden_US
dc.titleThe hepatotoxicity of non-steroidal anti-inflammatory drugsen_US
dc.typeArticleen_US
dc.subject.hlbsecondlevelOtolaryngologyen_US
dc.subject.hlbsecondlevelPharmacy and Pharmacologyen_US
dc.subject.hlbtoplevelHealth Sciencesen_US
dc.description.peerreviewedPeer Revieweden_US
dc.contributor.affiliationum* Division of Gastroenterology, University of Michigan Health System, Ann Arbor, MI, USAen_US
dc.contributor.affiliationother† Gastroenterology Division, University of Southern California School of Medicine, Los Angeles, CA, USAen_US
dc.identifier.pmid15298630en_US
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/72868/1/j.1365-2036.2004.02092.x.pdf
dc.identifier.doi10.1111/j.1365-2036.2004.02092.xen_US
dc.identifier.sourceAlimentary Pharmacology & Therapeuticsen_US
dc.identifier.citedreferenceTalley NJ, Evans JM, Fleming KC, Harmsen WS, Zinsmeister AR, Melton LJ III. Nonsteroidal anti-inflammatory drugs and dyspepsia in the elderly. Dig Dis Sci 1995; 40: 1345 – 50.en_US
dc.identifier.citedreferenceLaine L. Approaches to nonsteroidal anti-inflammatory drug use in the high-risk patient. Gastroenterology 2001; 120: 594 – 606.en_US
dc.identifier.citedreferenceTeoh NC, Farrell GC. Hepatotoxicity associated with non-steroidal anti-inflammatory drugs. Clin Liver Dis 2003; 7: 401 – 13.en_US
dc.identifier.citedreferenceMerlani G, Fox M, Oehen HP, et al. Fatal hepatoxicity secondary to nimesulide. Eur J Clin Pharmacol 2001; 57: 321 – 6.en_US
dc.identifier.citedreferenceRabkin JM, Smith MJ, Orloff SL, Corless CL, Stenzel P, Olyaei AJ. Fatal fulminant hepatitis associated with bromfenac use. Ann Pharmacother 1999; 33: 945 – 7.en_US
dc.identifier.citedreferenceMcCormick PA, Kennedy F, Curry M, Traynor O. COX 2 inhibitor and fulminant hepatic failure [see comment]. Lancet 1999; 353: 40 – 1.en_US
dc.identifier.citedreferenceMabee CL, Mabee SW, Baker PB, Kirkpatrick RB, Levine EJ. Fulminant hepatic failure associated with etodolac use. Am J Gastroenterol 1995; 90: 659 – 61.en_US
dc.identifier.citedreference8 Anonymous. Bromfenac withdrawal. WHO Drug Inf 1998; 12: 146.en_US
dc.identifier.citedreferenceMiwa LJ, Jones JK, Pathiyal A, Hatoum H. Value of epidemiologic studies in determining the true incidence of adverse events. The nonsteroidal anti-inflammatory drug story. Arch Intern Med 1997; 157: 2129 – 36.en_US
dc.identifier.citedreferenceHarris RP, Helfand M, Woolf SH, et al. Current methods of the US Preventive Services Task Force: a review of the process. Am J Prev Med 2001; 20 ( Suppl. 3 ): 21 – 35.en_US
dc.identifier.citedreferenceCiccolunghi SN, Chaudri HA, Schubiger BI, Reddrop R. Report on a long-term tolerability study of up to two years with diclofenac sodium (Voltaren). Scand J Rheumatol 1978; Suppl. 22: 86 – 96.en_US
dc.identifier.citedreferenceGarcia Rodriguez LA, Perez Gutthann S, Walker AM, Lueck L. The role of non-steroidal anti-inflammatory drugs in acute liver injury. BMJ 1992; 305: 865 – 8.en_US
dc.identifier.citedreferenceJick H, Derby LE, Garcia Rodriguez LA, Jick SS, Dean AD. Liver disease associated with diclofenac, naproxen, and piroxicam. Pharmacotherapy 1992; 12: 207 – 12.en_US
dc.identifier.citedreferenceWalker AM, Cavanaugh RJ. The occurrence of new hepatic disorders in a defined population. Post-marketing Surveill 1992; 6: 107 – 17.en_US
dc.identifier.citedreferenceCarson JL, Strom BL, Duff A, Gupta A, Das K. Safety of nonsteroidal anti-inflammatory drugs with respect to acute liver disease. Arch Intern Med 1993; 153: 1331 – 6.en_US
dc.identifier.citedreferencePerez Gutthann S, Garcia Rodriguez LA. The increased risk of hospitalizations for acute liver injury in a population with exposure to multiple drugs. Epidemiology 1993; 4: 496 – 501.en_US
dc.identifier.citedreferenceGarcia Rodriguez LA, Williams R, Derby LE, Dean AD, Jick H. Acute liver injury associated with nonsteroidal anti-inflammatory drugs and the role of risk factors. Arch Intern Med 1994; 154: 311 – 6.en_US
dc.identifier.citedreferenceLanza LL, Walker AM, Bortnichak EA, Gause DO, Dreyer NA. Incidence of symptomatic liver function abnormalities in a cohort of NSAID users. Pharmacoepidemiol Drug Saf 1995; 4: 231 – 7.en_US
dc.identifier.citedreferenceTrechot P, Gillet P, Gay G, et al. Incidence of hepatitis induced by non-steroidal anti-inflammatory drugs. Ann Rheum Dis 1996; 55: 936.en_US
dc.identifier.citedreferenceDuh M, Walker AM, Kronlund KH Jr. Descriptive epidemiology of acute liver enzyme abnormalities in the general population of central Massachusetts. Pharmacoepidemiol Drug Saf 1999; 8: 275 – 83.en_US
dc.identifier.citedreferencePerez-Gutthann S, Garcia-Rodriguez LA, Duque-Oliart A, Varas-Lorenzo C. Low-dose diclofenac, naproxen, and ibuprofen cohort study. Pharmacotherapy 1999; 19: 854 – 9.en_US
dc.identifier.citedreferenceMartin RM, Biswas P, Mann RD. The incidence of adverse events and risk factors for upper gastrointestinal disorders associated with meloxicam use amongst 19,087 patients in general practice in England: cohort study. Br J Clin Pharmacol 2000; 50: 35 – 42.en_US
dc.identifier.citedreferenceIban  ez L, Perez E, Vidal X, Laporte JR. Prospective surveillance of acute serious liver disease unrelated to infectious, obstructive, or metabolic diseases: epidemiological and clinical features, and exposure to drugs. J Hepatol 2002; 37: 592 – 600.en_US
dc.identifier.citedreferenceSgro C, Clinard F, Ouazir K, et al. Incidence of drug-induced hepatic injuries: a French population-based study. Hepatology 2002; 36: 451 – 5.en_US
dc.identifier.citedreferencePaulose-Ram R, Hirsch R, Dillon C, Losonczy K, Cooper M, Ostchega Y. Prescription and non-prescription analgesic use among the US adult population: results from the third National Health and Nutrition Examination Survey (NHANES III). Pharmacoepidemiol Drug Saf 2003; 12: 315 – 26.en_US
dc.identifier.citedreferenceTraversa G, Bianchi C, DaCas R, Abraha I, Menniti-Ippolito F, Venegoni M. Cohort study of hepatotoxicity associated with nimesulide and other non-steroidal anti-inflammatory drugs. BMJ 2003; 327: 18 – 22.en_US
dc.identifier.citedreferenceJick H, Walker AM, Porter J. Drug-induced liver disease. J Clin Pharmacol 1981; 21: 359 – 64.en_US
dc.identifier.citedreferenceLaine L. Gastrointestinal effects of NSAIDs and coxibs. J Pain Symptom Manage 2003; 25 ( Suppl. 2 ): 32 – 40.en_US
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Name:
j.1365-2036.2004.02092.x.pdf
Size:
73.99KB
Format:
PDF
View/Open

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.